Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib with Gemcitabine and Carboplatin in Refractory Testicular Germ Cell Cancer
NCT02860819Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of veliparib in testicular germ cell cancer (TGCC), sponsored by National Cancer Institute. Started Aug 2016; status: completed.
02
Drugs
veliparib
03
Conditions
testicular germ cell cancer (TGCC)
Beyond the preview
Go deeper on NCT02860819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860819.